Abbott, Fisher unit collaborate on drug discovery
Last Updated on Saturday, 15 July 2006 06:58 Written by admin Saturday, 15 July 2006 06:58
NEW YORK, July 6 (Reuters) – Drug maker Abbott Laboratories Inc. (ABT.N: Quote, Profile, Research) and a unit of medical devices company Fisher Scientific International Inc. (FSH.N: Quote, Profile, Research) on Thursday said they would collaborate on developing new therapeutics.
The companies said the research could extend drug discovery efforts into disease targets where traditional technologies have not succeeded. The collaboration will involve a gene silencing technology, they said.
Financial terms of the agreement between Abbott and Fisher’s Dharmacon Inc. unit were not announced.
Main Menu
- Home
- About Bioscreening.net
- Glossary
- Biotechnology Glossary A-I
- Biotechnology Glossary J-Q
- Biotechnology Glossary R-Z
- Bird Flu
- Cheminformatic Glossary
- Endotoxins
- Fullerenes
- Genipin
- Gossypol (Gossipol)
- Grants, Venture Capital, and Government Funding
- High-throughput screening
- Lipinski Rule-of-Five
- Mumie
- Natural Medicine
- Rule-of-Three (Ro3)
- Targeted Libraries
- Web Directory